Patents by Inventor Mary P. Lambert
Mary P. Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210386879Abstract: A method for detecting soluble oligomeric amyloid ? in a subject is provided.Type: ApplicationFiled: August 25, 2021Publication date: December 16, 2021Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Publication number: 20170209604Abstract: A method for detecting soluble oligomeric amyloid ? in a subject using, e.g., PET is provided.Type: ApplicationFiled: April 11, 2017Publication date: July 27, 2017Applicant: Northwestern UniversityInventors: Grant A. Krafft, William L. Klein, Brett A Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Publication number: 20160213794Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: March 29, 2016Publication date: July 28, 2016Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20140322731Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: February 26, 2014Publication date: October 30, 2014Applicant: Northwestern UniversityInventors: Grant A. Krafft, William L. Klein, David W. Summa, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola, Yue Song Gong
-
Publication number: 20130330837Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods utilizing such antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: ApplicationFiled: July 16, 2013Publication date: December 12, 2013Applicants: Acumen Pharmaceuticals, Inc., Northwestern UniversityInventors: Mary P. Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Publication number: 20130236466Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: November 14, 2012Publication date: September 12, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Patent number: 8507206Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: GrantFiled: July 5, 2005Date of Patent: August 13, 2013Assignees: Northwestern University, Acumen Pharmaceuticals, Inc.Inventors: Mary P Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Patent number: 8383113Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: February 8, 2012Date of Patent: February 26, 2013Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20120171224Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: February 8, 2012Publication date: July 5, 2012Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Patent number: 8128930Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: July 1, 2010Date of Patent: March 6, 2012Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20110159013Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: October 11, 2010Publication date: June 30, 2011Applicant: Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20100272714Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: July 1, 2010Publication date: October 28, 2010Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Patent number: 7811563Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 21, 2005Date of Patent: October 12, 2010Assignees: Northwestern University, Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 7780963Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ?1-42.Type: GrantFiled: October 21, 2005Date of Patent: August 24, 2010Assignees: Merck & Co., Inc., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola
-
Patent number: 7638283Abstract: The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid ? peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.Type: GrantFiled: May 16, 2005Date of Patent: December 29, 2009Assignees: Northwestern University, University of Southern CaliforniaInventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Mary P. Lambert, Caleb E. Finch, Todd Morgan, Pat Wals, Irina Rozovsky, Ann Barlow
-
Publication number: 20090285804Abstract: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.Type: ApplicationFiled: June 17, 2009Publication date: November 19, 2009Inventors: William L. Klein, Grant A. Krafft, Mary P. Lambert, Kirsten L. Viola, Brett A. Chromy, Lei Chang
-
Publication number: 20080306074Abstract: Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise.Type: ApplicationFiled: May 16, 2005Publication date: December 11, 2008Inventors: Pascale N. Lacor, Kirsten L. Viola, Mary P. Lambert, Yeusong Gong, Lei Chang, Pauline T. Velasco, Eileen H. Bigio, Maria C. Buniel, Sara J. Fernandez, Jasna Jerecic, Susan Catalano, Todd Pray, Ray Lowe, Grant A. Krafft, William L. Klein
-
Publication number: 20080175835Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: October 21, 2005Publication date: July 24, 2008Applicants: Merck & Co., Inc., Northwestern UniversityInventors: Paul Acton, Zhigiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20080176252Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: June 1, 2005Publication date: July 24, 2008Inventors: Grant A. Krafft, William L. Klein, David W. Summa, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola, Yuesong Gong